For instance, in case of the individualized peptide‐based neoantigen: the collected sample tumor should be sequenced and the neoantigen identification performed using computational tools (considering factors such as predictive proteasome processing and MHC class‐I and‐II binding affinities) and mass spectrometry, followed by custom synthesis of the identified neoantigens; the customized neoantigens are mixed with adjuvants and administered to patients.[24]. The gene discussed is HLA-C; the disease is neoplasm.